GT Biopharma Inc (GTBP)vsInsmed Inc (INSM)
GTBP
GT Biopharma Inc
$0.47
-2.13%
HEALTHCARE · Cap: $14.52M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
GTBP leads profitability with a 0.0% profit margin vs -2.1%. GTBP appears more attractively valued with a PEG of 1.05. INSM earns a higher WallStSmart Score of 39/100 (F).
GTBP
Avoid29
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GTBP
The strongest argument for GTBP centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : GTBP
The primary concerns for GTBP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
GTBP profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
GTBP carries more volatility with a beta of 1.19 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
GTBP generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GT Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?